[Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].
Keil
U
U
Fortschritte der Medizin, Urban & Vogel GmbH, München.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077300:Bosentan; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology; D017315:Cilazapril / Q000009:adverse effects / Q000627:therapeutic use*; D016232:Endothelins / Q000037:antagonists & inhibitors*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D020748:Mibefradil; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D016232:Endothelins; D013449:Sulfonamides; D013764:Tetrahydronaphthalenes; D017315:Cilazapril; D020748:Mibefradil; D000077300:Bosentan